

Patrizia Chiusolo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3044153/publications.pdf>

Version: 2024-02-01

253
papers

6,493
citations

81743

39
h-index

82410

72
g-index

262
all docs

262
docs citations

262
times ranked

7550
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of netupitant/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkinâ€™s lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation. Supportive Care in Cancer, 2022, 30, 1521-1527.	1.0	2
2	GITMO Registry Study on Allogeneic Transplantation in Patients Aged â‰¥60 Years from 2000 to 2017: Improvements and Criticisms. Transplantation and Cellular Therapy, 2022, 28, 96.e1-96.e11.	0.6	13
3	Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study. Haematologica, 2022, 107, 996-999.	1.7	15
4	Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants. Bone Marrow Transplantation, 2022, 57, 532-537.	1.3	6
5	Hemorrhagic cystitis in allogeneic stem cell transplantation: a role for age and prostatic hyperplasia. Supportive Care in Cancer, 2022, 30, 4953-4959.	1.0	4
6	Successful Second Autologous Stem Cell Transplantation for Late Disease Progression after the First Procedure in POEMS Syndrome. Applied Sciences (Switzerland), 2022, 12, 2577.	1.3	1
7	Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma. Bone Marrow Transplantation, 2022, 57, 837-839.	1.3	4
8	The day 100 score predicts moderate to severe cGVHD, transplant mortality, and survival after hematopoietic cell transplantation. Blood Advances, 2022, 6, 2309-2318.	2.5	1
9	Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01. Bone Marrow Transplantation, 2022, 57, 949-958.	1.3	7
10	COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report. Haematologica, 2022, 107, 1955-1959.	1.7	6
11	Deciphering the effects of graft Tregs on chronic graft-versus-host disease: results from a prospective, multicenter study in patients with acute leukemia undergoing allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplantation, 2022, , .	1.3	0
12	Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen. American Journal of Hematology, 2021, 96, 234-240.	2.0	14
13	Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation. Hematological Oncology, 2021, 39, 267-269.	0.8	1
14	Inline and offline extracorporeal photopheresis: Device performance, cell yields and clinical response. Journal of Clinical Apheresis, 2021, 36, 118-126.	0.7	9
15	Second haploidentical stem cell transplantation for primary graft failure. Bone Marrow Transplantation, 2021, 56, 1291-1296.	1.3	14
16	Allelic HLA Matching and Pair Origin Are Favorable Prognostic Factors for Unrelated Hematopoietic Stem Cell Transplantation in Neoplastic Hematologic Diseases: An Italian Analysis by the Gruppo Italiano Trapianto di Cellule Staminali e Terapie Cellulari, Italian Bone Marrow Donor Registry, and Associazione Italiana di Immunogenetica e Biologia dei Trapianti. Transplantation and Cellular Therapy, 2021, 27, 406.e1-406.e11.	0.6	4
17	Sudden death of a SARSâ€CoVâ€2 patient with NPM1â€+â€acute myeloid leukemia mimicking acute promyelocytic leukemia. International Journal of Laboratory Hematology, 2021, 43, 341-342.	0.7	3
18	Thiotepaâ€busulfanâ€fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplantation, 2021, 56, 1593-1602.	1.3	8

#	ARTICLE	IF	CITATIONS
19	Prognostic factors for neutrophil engraftment after haploidentical cell transplantation with PT-Cy in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMT. Bone Marrow Transplantation, 2021, 56, 1842-1849.	1.3	4
20	Outcome of Tâ€cellâ€replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer, 2021, 127, 2507-2514.	2.0	8
21	Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed/refractory bâ€precursor acute lymphoblastic leukaemia: Case reports and literature review. Pediatric Blood and Cancer, 2021, 68, e29044.	0.8	7
22	Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study. International Journal of Hematology, 2021, 114, 228-234.	0.7	16
23	EXTRAMEDULLARY INVOLVEMENT IN ACUTE MYELOID LEUKEMIA. A SINGLE CENTER TEN YEARS EXPERIENCE. Mediterranean Journal of Hematology and Infectious Diseases, 2021, 13, e2021030.	0.5	15
24	Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021. Frontiers in Immunology, 2021, 12, 637512.	2.2	9
25	Use of DPB1 Tâ€cell epitope algorithm among italian transplant centers: A survey on behalf of Associazione Italiana di Immunogenetica e Biologia dei Trapianti. Hla, 2021, 98, 114-121.	0.4	2
26	Coronavirus disease 2019 pandemic and allogeneic hematopoietic stem cell transplantation: a single center reappraisal. Cytotherapy, 2021, 23, 635-640.	0.3	14
27	ABO Mismatch in Allogeneic Hematopoietic Stem Cell Transplant: Effect on Short- and Long-term Outcomes. Transplantation Direct, 2021, 7, e724.	0.8	2
28	Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience. Frontiers in Oncology, 2021, 11, 614721.	1.3	6
29	The Impact of Graft CD3 Cell/Regulatory T Cell Ratio on Acute Graft-versus-Host Disease and Post-Transplantation Outcome: A Prospective Multicenter Study of Patients with Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 918.e1-918.e9.	0.6	3
30	A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19. Scientific Reports, 2021, 11, 21136.	1.6	14
31	IS ALLOGENEIC TRANPLANTATION AN OPTION IN PATIENTS AFFECTED BY CONCURRENT MYELOFIBROSIS AND CHRONIC MYELOID LEUKEMIA (CML)? Mediterranean Journal of Hematology and Infectious Diseases, 2021, 13, e2021062.	0.5	2
32	Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T). Mediterranean Journal of Hematology and Infectious Diseases, 2021, 13, e2021066.	0.5	3
33	Bone marrow megakaryocytic activation predicts fibrotic evolution of Philadelphia-negative myeloproliferative neoplasms. Haematologica, 2021, 106, 3162-3169.	1.7	4
34	ACUTE Lymphoblastic Leukemia (ALL) and COVID-19 Infection. a Campus ALL Report. Blood, 2021, 138, 216-216.	0.6	0
35	Triple Post-Transplant Cyclophosphamide (PTCY) Based Gvhd Prophylaxis for HLA Matched or HLA Haploidentical Transplants. Blood, 2021, 138, 4881-4881.	0.6	0
36	Successful â€œonâ€demandâ€plerixafor for autologous peripheral blood stemâ€cells transplantation for relapsed/refractory germ cell tumors. Journal of Clinical Apheresis, 2021, , .	0.7	2

#	ARTICLE	IF	CITATIONS
37	Hematologic Recovery after Allogeneic Transplantation: Risk Factors and Its IMPACT on Transplant Related Mortality. <i>Blood</i> , 2021, 138, 2867-2867.	0.6	1
38	Overall Survival Improvement Following ALLO-SCT in Patients Older THAN 60 YEARS: A Gruppo Italiano Trapianto DI Midollo Osseo (GITMO) Registry Study. <i>Blood</i> , 2021, 138, 1786-1786.	0.6	0
39	Real-Life CAR-T Cell Treatment in Large B-Cell Lymphomas Indicates That Axi-Cel and Tisa-Cel Have Similar Outcomes, but Long-Term Cytopenia Is an Emerging Problem. <i>Blood</i> , 2021, 138, 3867-3867.	0.6	3
40	Cytomegalovirus and Epstein Barr Virus Reactivation after Allogeneic Stem Cell Transplantation in Pre- and Post-Letermovir Era. <i>Blood</i> , 2021, 138, 1782-1782.	0.6	1
41	The Impact of Age in Allogeneic Stem Cell Transplantation with Thiotepa Busulfan and Fludarabine (TBF) for Myelofibrosis : A Retrospective Analysis. <i>Blood</i> , 2021, 138, 4858-4858.	0.6	0
42	Chronic Myeloid Leukemia in a Patient with Previous Idiopathic Thrombocytopenic Purpura: How to Manage Imatinib Together with Eltrombopag. <i>Medicina (Lithuania)</i> , 2021, 57, 1326.	0.8	1
43	JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis. <i>Blood Cancer Journal</i> , 2021, 11, 199.	2.8	47
44	Treatment of primary plasma cell leukemia with high doses of cyclophosphamide, bortezomib, and dexamethasone followed by double autologous HSCT. <i>Annals of Hematology</i> , 2020, 99, 207-209.	0.8	1
45	Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 698-703.	2.0	19
46	Timing of Post-Transplantation Cyclophosphamide Administration in Haploidentical Transplantation: A Comparative Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1915-1922.	2.0	24
47	Increased CD95 (Fas) and PD-1 expression in peripheral blood T lymphocytes in COVID-19 patients. <i>British Journal of Haematology</i> , 2020, 191, 207-211.	1.2	84
48	Impact of donor age and kinship on clinical outcomes after T-cell replete haploidentical transplantation with PT-Cy. <i>Blood Advances</i> , 2020, 4, 3900-3912.	2.5	30
49	SARS CoV 2 infection in chronic myelogenous leukemia: Severe hematological presentation. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102881.	0.5	6
50	Pre-Exposure to Defibrotide Prevents Endothelial Cell Activation by Lipopolysaccharide: An Ingenuity Pathway Analysis. <i>Frontiers in Immunology</i> , 2020, 11, 585519.	2.2	7
51	ALL-159: A Retrospective Real-Life Report on Newly Diagnosed Adult Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL) Patients Treated in Italy - The CAMPUS-ALL Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S162.	0.2	0
52	Allogeneic cord blood transfusions prevent fetal haemoglobin depletion in preterm neonates. Results of the CB-TRIP study. <i>British Journal of Haematology</i> , 2020, 191, 263-268.	1.2	21
53	Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibody "Begelomab. <i>Bone Marrow Transplantation</i> , 2020, 55, 1580-1587.	1.3	21
54	Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs. <i>Annals of Hematology</i> , 2020, 99, 867-875.	0.8	8

#	ARTICLE	IF	CITATIONS
55	Bone marrow haploidentical transplant with post-transplantation cyclophosphamide: does graft cell content have an impact on main clinical outcomes?. <i>Cytotherapy</i> , 2020, 22, 158-165.	0.3	10
56	Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin's lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study. <i>Bone Marrow Transplantation</i> , 2020, 55, 2114-2120.	1.3	11
57	Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long-term follow up of a phase III study. <i>American Journal of Hematology</i> , 2020, 95, 749-758.	2.0	12
58	DAYS ALIVE OUTSIDE HOSPITAL AND RE-ADMISSIONS IN PATIENTS UNDERGOING ALLOGENEIC TRANSPLANTS FROM IDENTICAL SIBLINGS, UNRELATED DONORS OR HAPLOIDENTICAL DONORS. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020055.	0.5	4
59	Similar Molecular Pattern in Therapy Related Acute Myeloid Leukemia in Patients Treated with Purp Inhibitors for Metastatic Ovarian Cancer. <i>Blood</i> , 2020, 136, 40-40.	0.6	0
60	Graft versus host disease in unmanipulated haploidentical marrow transplantation with a modified post-transplant cyclophosphamide (PT-CY) regimen: an update on 425 patients. <i>Bone Marrow Transplantation</i> , 2019, 54, 708-712.	1.3	22
61	Secondary chronic myeloid leukemia: comparison between patients previously exposed or not to chemo- and/or radiotherapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 3584-3586.	0.6	5
62	Preoperative autologous blood donation in adult bone marrow donors: reappraisal of a single-centre experience. <i>Vox Sanguinis</i> , 2019, 114, 762-768.	0.7	4
63	Peripheral Blood Hemopoietic Stem Cell Mobilization Regimens in POEMS Syndrome: A Retrospective Study at 2 Hematologic Italian Centers. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2514-2516.	2.0	5
64	The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview. <i>Leukemia</i> , 2019, 33, 1173-1183.	3.3	83
65	Inline extracorporeal photopheresis: evaluation of cell collection efficiency. <i>Transfusion</i> , 2019, 59, 3714-3720.	0.8	6
66	Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2019, 104, 312-318.	1.7	54
67	Unrelated cord blood transplantation and post-transplant cyclophosphamide. <i>Haematologica</i> , 2019, 104, e77-e78.	1.7	10
68	Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid. <i>Leukemia and Lymphoma</i> , 2019, 60, 1328-1330.	0.6	2
69	Full Donor Chimerism after Allografts for Myelofibrosis: The Role of Conditioning Regimen. <i>Blood</i> , 2019, 134, 4490-4490.	0.6	0
70	Unrelated Cord Blood Transplantation and Post-Transplant Cyclophosphamide (PT-CY). <i>Blood</i> , 2019, 134, 3332-3332.	0.6	0
71	The Impact of Aminoacid Substitution at Position 116 Class I HLA, in Unrelated Donor Transplants. <i>Blood</i> , 2019, 134, 4620-4620.	0.6	0
72	Phase II Multicenter, Not Comparative, Study of Multiple Doses of NEPA (netupitant + palonosetron) in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in Non-Hodgkin Lymphoma Patients Eligible for Autologous Hematopoietic Stem Cell Transplantation Receiving Multiple Days / High Dose Chemotherapy Regimens. <i>Blood</i> , 2019, 134, 1974-1974.	0.6	0

#	ARTICLE	IF	CITATIONS
73	The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1322-1340.	2.0	85
74	Allogeneic Transplant for Mycosis Fungoides in Patient with Wiskott-Aldrich Syndrome. <i>Journal of Clinical Immunology</i> , 2018, 38, 7-9.	2.0	2
75	A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1243-1249.	2.0	49
76	Myeloablative Versus Nonmyeloablative Conditioning Regimen in Haploidentical Transplantation: Does It Matter and How Best to Select Between the Two?. , 2018, , 159-171.		0
77	Mononuclear cell collection for extracorporeal photopheresis: Concentrate characteristics for off-line UV-A irradiation procedure. <i>Journal of Clinical Apheresis</i> , 2018, 33, 217-221.	0.7	6
78	Autologous peripheral blood stem cell transplantation and the role of lenalidomide in patients affected by poeems syndrome. <i>Hematological Oncology</i> , 2018, 36, 392-398.	0.8	6
79	Role of flow cytometric immunophenotyping in prediction of <i>BCR/ABL1</i> gene rearrangement in adult acute lymphoblastic leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 468-476.	0.7	14
80	Foscarnet treatment of cytomegalovirus infection in haploidentical or unrelated donor transplants. <i>Bone Marrow Transplantation</i> , 2018, 53, 1560-1567.	1.3	5
81	A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1814-1822.	2.0	18
82	Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>British Journal of Haematology</i> , 2018, 183, 411-420.	1.2	27
83	EARLY Post-Transplant Events , Cost of Admission and Mortality, in Patients Undergoing Allogeneic Transplants from Identical Siblings, Unrelated Donors or Haploidentical Donors. <i>Blood</i> , 2018, 132, 4648-4648.	0.6	0
84	Unmanipulated Haploidentical Marrow Transplantation with a Modified Post-Transplant Cyclophosphamide (PT-CY) Regimen: An Update on 444 Patients. <i>Blood</i> , 2018, 132, 3351-3351.	0.6	0
85	High Resolution Donor/Recipient HLA Matching Level in Unrelated Hematopoietic Stem Cell Transplantation and Impact on the Transplant Outcome: The Italian Experience on Behalf of GITMO, IBMDR and Aibt. <i>Blood</i> , 2018, 132, 4642-4642.	0.6	0
86	"Secondary Chronic Myeloid Leukemia": Comparison between Patients Previously Exposed or Not to Chemo and/or Radiotherapy. <i>Blood</i> , 2018, 132, 5437-5437.	0.6	2
87	Which Is the Best Mobilizing Regimen in POEMS Syndrome? a Retrospective Italian Study of Two Haematological Centres. <i>Blood</i> , 2018, 132, 5692-5692.	0.6	1
88	Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Bone Marrow Transplantation</i> , 2017, 52, 955-961.	1.3	20
89	Fecal but not serum calprotectin is a potential marker of GVHD after stem cell transplantation. <i>Annals of Hematology</i> , 2017, 96, 929-933.	0.8	10
90	Hyperleukocytosis and leukostasis: management of a medical emergency. <i>Expert Review of Hematology</i> , 2017, 10, 147-154.	1.0	49

#	ARTICLE	IF	CITATIONS
91	Steroid treatment of acute graft-versus-host disease grade I: a randomized trial. <i>Haematologica</i> , 2017, 102, 2125-2133.	1.7	27
92	Changes in protein serum levels during stem cell transplantation. <i>European Journal of Clinical Investigation</i> , 2017, 47, 711-718.	1.7	3
93	Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2017, 58, 993-995.	0.6	10
94	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THERAPY-RELATED MYELOID NEOPLASMS (t-MN) OF THE ADULT: MONOCENTRIC OBSERVATIONAL STUDY AND REVIEW OF THE LITERATURE.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2017, 10, 2018005.	0.5	9
95	Busulfan Fludarabine (BU-FLU) Compared to Thiotepa Busulfan Fludarabine (TBF) for Allogeneic Transplants in Acute Myeloid Leukemia (AML) or Refractory Anemia with Excess Blasts (RAEB) in Remission. <i>Blood</i> , 2017, 130, 909-909.	0.6	2
96	THE GUT MICROBIOTA AND IMMUNE SYSTEM RELATIONSHIP IN HUMAN GRAFT-VERSUS-HOST DISEASE. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 8, 2016025.	0.5	53
97	Massive pulmonary embolism at the onset of acute promyelocytic leukemia. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 8, 2016027.	0.5	4
98	Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host Disease. <i>Transplantation</i> , 2016, 100, e147-e155.	0.5	40
99	Cytokine profile of autologous platelet-derived eye drops in patients with ocular chronic graft-versus-host disease. <i>Vox Sanguinis</i> , 2016, 110, 189-192.	0.7	9
100	Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience. <i>Leukemia and Lymphoma</i> , 2016, 57, 2429-2431.	0.6	10
101	the Polymorphisms on Chromosome 9p21 Play a Role in the Risk for Cardiovascular Events in Chronic Myeloid Leukemia Patients?. <i>Blood</i> , 2016, 128, 5100-5100.	0.6	0
102	A Modified Post-Transplant Cyclophosphamide (PT-CY) Regimen, Following Unmanipulated Haploidentical Bone Marrow Transplantation, for Acute Myeloid Leukemia: A Multicenter Study. <i>Blood</i> , 2016, 128, 1234-1234.	0.6	7
103	Clinical Reversible Myelopathy in T-Cell Lymphoblastic Lymphoma Treated with Nelarabine and Radiotherapy: Report of a Case and Review of Literature of an Increasing Complication. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2015, 7, e2015025.	0.5	6
104	Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1525-1536.	5.1	143
105	Infections by carbapenem-resistant <i>Klebsiella pneumoniae</i> in SCT recipients: a nationwide retrospective survey from Italy. <i>Bone Marrow Transplantation</i> , 2015, 50, 282-288.	1.3	142
106	Gut Microbiome Changes after Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 1953-1953.	0.6	9
107	Granulocyte Transfusions at Appropriate Doses Improve Survival in Hematological Patients with Febrile Neutropenia. <i>Blood</i> , 2015, 126, 3566-3566.	0.6	0
108	Methylenetetrahydrofolate reductase polymorphisms in myelodysplastic syndromes and therapy-related myeloid neoplasms. <i>Leukemia and Lymphoma</i> , 2014, 55, 2942-2944.	0.6	4

#	ARTICLE	IF	CITATIONS
109	Extreme thrombocytosis in chronic myeloid leukemia in the era of tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2014, 55, 2958-2960.	0.6	7
110	Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide. <i>Transfusion</i> , 2014, 54, 2514-2522.	0.8	75
111	Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Stem Cell Transplantation: A Prospective Study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 872-880.	2.0	141
112	The role of the MTHFR 677C>T polymorphism in methotrexate-induced liver toxicity: a meta-analysis in patients with cancer. <i>Pharmacogenomics Journal</i> , 2014, 14, 115-119.	0.9	27
113	Carbapenem-Resistant Enterobacteriaceae (CRE) and Their Impact on Stem Cell Transplantation: A Single Center Experience. <i>Blood</i> , 2014, 124, 3880-3880.	0.6	9
114	Randomized Trial of Busulfan with Cyclophosphamide Versus Busulfan with Fludarabine As Preparative Regimen to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia: A Study from the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Blood</i> , 2014, 124, 727-727.	0.6	1
115	Factors Predicting Outcome after Allogeneic Stem Cell Transplantation in Primary Refractory Acute Myeloid Leukemia: A Retrospective Analysis of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). <i>Blood</i> , 2014, 124, 731-731.	0.6	0
116	Isolation, Expansion and Characterization of BM-Mesenchymal Cells (MSCs) in Patients Affected By Chronic Myeloproliferative neoplasm (MPN). <i>Blood</i> , 2014, 124, 5142-5142.	0.6	1
117	Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2013, 88, 581-588.	2.0	61
118	Peripherally inserted central catheters (PICCs) in the management of oncohematological patients submitted to autologous stem cell transplantation. <i>Supportive Care in Cancer</i> , 2013, 21, 531-535.	1.0	50
119	Salivary Proteomic Analysis and Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 888-892.	2.0	17
120	Twenty years of unrestricted hematopoietic stem cell collection and storage: impact of Joint Accreditation Committee International Society for Cellular Therapy Europe standards implementation on stem cell storage policy and resource utilization. <i>Cytotherapy</i> , 2013, 15, 519-521.	0.3	5
121	Complete Remission Obtained with Azacitidine in a Patient with Concomitant Therapy Related Myeloid Neoplasm and Pulmonary Mucormycosis. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2013, 5, e2013048.	0.5	2
122	Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases. <i>Leukemia</i> , 2013, 27, 982-985.	3.3	22
123	Donor erythrocytosis induced by sorafenib treatment after allogeneic hematopoietic SCT in a patient with acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2012, 47, 872-873.	1.3	7
124	Correlation between paraproteinaemia and viral reactivation after allo-SCT. <i>Bone Marrow Transplantation</i> , 2012, 47, 1262-1262.	1.3	1
125	The role of HLA-G 14-bp polymorphism in allo-HSCT after short-term course MTX for GvHD prophylaxis. <i>Bone Marrow Transplantation</i> , 2012, 47, 120-124.	1.3	30
126	Role of fecal calprotectin as biomarker of gastrointestinal GVHD after allogeneic stem cell transplantation. <i>Blood</i> , 2012, 120, 4443-4444.	0.6	22

#	ARTICLE	IF	CITATIONS
127	High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2012, 87, E133.	2.0	2
128	Outcome of concurrent acute myeloid leukemia and granulocytic sarcoma: three clinical cases and a review of the literature. <i>Comparative Clinical Pathology</i> , 2012, 21, 725-730.	0.3	0
129	Role of 18F-FDG PET-CT for evaluating the response to reduced-intensity conditioning allogeneic transplant in heavily pre-treated patients with chronic lymphocytic leukemia: preliminary results in nine patients. <i>Annals of Nuclear Medicine</i> , 2012, 26, 764-768.	1.2	1
130	Efficacy of lenalidomide plus dexamethasone for POEMS syndrome relapsed after autologous peripheral stem cell transplantation. <i>American Journal of Hematology</i> , 2012, 87, 641-642.	2.0	24
131	The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 691-696.	1.1	40
132	In Patient with Chronic Lymphocytic Leukemia the Overall SURVIVAL Is NOT Different WHEN Analysed by Cause of Death, Related or NOT Related to the Disease. <i>Blood</i> , 2012, 120, 4587-4587.	0.6	0
133	Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome. <i>Annals of Hematology</i> , 2011, 90, 59-65.	0.8	13
134	JAK2 V617F mutational frequency in essential thrombocythemia associated with splanchnic or cerebral vein thrombosis. <i>American Journal of Hematology</i> , 2011, 86, 526-528.	2.0	31
135	Reduced-intensity conditioning allogeneic transplant in heavily pre-treated chronic lymphocytic leukaemia patients: a single centre experience. <i>Hematological Oncology</i> , 2011, 29, 107-110.	0.8	2
136	Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogeneic stem cell transplantation. <i>Leukemia Research</i> , 2011, 35, 422-423.	0.4	19
137	Prospective Evaluation of Epstein-Barr Virus Reactivation After Stem Cell Transplantation: Association with Monoclonal Gammopathy. <i>Journal of Clinical Immunology</i> , 2010, 30, 894-902.	2.0	19
138	ALLOGENEIC TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2010, 2, e2010026.	0.5	2
139	Low-Dose Valganciclovir as Preemptive Therapy for Cytomegalovirus Infection Occurring in Allogeneic Stem Cell Transplant Recipients. <i>Acta Haematologica</i> , 2010, 123, 230-234.	0.7	11
140	Platelet-lysate-Expanded Mesenchymal Stromal Cells as a Salvage Therapy for Severe Resistant Graft-versus-Host Disease in a Pediatric Population. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1293-1301.	2.0	165
141	Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms. <i>Blood Cells, Molecules, and Diseases</i> , 2010, 45, 181-185.	0.6	28
142	Circulating hematopoietic progenitor cells after autologous stem cell transplant for hematological malignancies. <i>Leukemia and Lymphoma</i> , 2010, 51, 1135-1138.	0.6	0
143	ROLE of Fecal Calprotectin as BIOMARKER of Gvhd AFTER Allogeneic STEM CELL TRANSPLANTATION. <i>Blood</i> , 2010, 116, 1253-1253.	0.6	0
144	DMSO Reduction Strategies Reduce DMSO Induced Post Autologous Transplant Morbidity In Patients with Lymphoma and Myeloma -Results from an EBMT Non Interventional Prospective Study. <i>Blood</i> , 2010, 116, 2397-2397.	0.6	0

#	ARTICLE	IF	CITATIONS
145	NEUROLOGIC IMPROVEMENT AFTER PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN POEMS. <i>Neurology</i> , 2009, 73, 1165-1166.	1.5	4
146	Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2009, 84, 126-127.	2.0	28
147	Reliability of leukostasis grading score to identify patients with high-risk hyperleukocytosis. <i>American Journal of Hematology</i> , 2009, 84, 381-382.	2.0	42
148	MTHFR Polymorphisms Involved in Vitamin B12 Deficiency Associated with Atrophic Gastritis. <i>Biochemical Genetics</i> , 2009, 47, 645-650.	0.8	6
149	Prevalence of the JAK2 V617F mutation in patients with unprovoked venous thromboembolism of common sites and without overt myeloproliferative neoplasms. <i>British Journal of Haematology</i> , 2009, 144, 965-967.	1.2	14
150	Incidence and clinical impact of extended-spectrum- β -lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by <i>Escherichia coli</i> in patients with hematological malignancies. <i>Journal of Infection</i> , 2009, 58, 299-307.	1.7	144
151	Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia. <i>Haematologica</i> , 2009, 94, 733-737.	1.7	51
152	Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation. <i>Blood</i> , 2009, 114, 1437-1444.	0.6	131
153	Epstein-Barr Virus Related Lymphoproliferations After Stem Cell Transplantation. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2009, 1, e2009019.	0.5	5
154	SDF1 Plasma Levels and CD34+ Cells Recirculation After Autologous Peripheral Blood Stem Cell Transplant. <i>Blood</i> , 2009, 114, 4571-4571.	0.6	0
155	Low incidence of secondary neoplasia after autotransplantation for lymphoproliferative disease: the role of pre-transplant therapy. <i>Clinical Transplantation</i> , 2008, 22, 191-199.	0.8	6
156	Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration. <i>Annals of Hematology</i> , 2008, 87, 891-898.	0.8	13
157	Early diagnosis followed by front-line autologous peripheral blood stem cell transplantation for patients affected by POEMS syndrome. <i>Leukemia Research</i> , 2008, 32, 1309-1312.	0.4	30
158	Clonal gammopathies and allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2008, 41, 317-317.	1.3	4
159	ABO type does not affect platelet engraftment after autologous peripheral blood stem cell transplant in a series of 249 hematologic patients. <i>Transfusion</i> , 2008, 48, 2645-2646.	0.8	1
160	Severe veno-occlusive disease after autologous peripheral blood stem cell transplantation for high-grade non-Hodgkin lymphoma: report of a successfully managed case and a literature review of veno-occlusive disease. <i>Clinical Transplantation</i> , 2008, 22, 837-841.	0.8	8
161	Chronic Lymphocytic Leukemia With Eyelid Involvement Responding to Alemtuzumab. <i>Journal of Clinical Oncology</i> , 2008, 26, 5299-5301.	0.8	1
162	Simultaneous double mismatched cord blood transplantation in a young patient with secondary myelodysplastic syndrome: Feasibility and complications. <i>Leukemia and Lymphoma</i> , 2008, 49, 821-823.	0.6	1

#	ARTICLE	IF	CITATIONS
163	WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Blood</i> , 2008, 112, 895-902.	0.6	192
164	The JAK2 V617F mutation in patients with cerebral venous thrombosis: A rebuttal. <i>Thrombosis and Haemostasis</i> , 2008, 99, 1121.	1.8	14
165	Reliability of Leukostasis Grading Score to Identify High Risk Patients with Hyperleukocytic Leukemia. <i>Blood</i> , 2008, 112, 2979-2979.	0.6	10
166	The Use of Low-Dose Alemtuzumab as Single Agent in the Treatment of Complication in Advanced Chronic Lymphocytic Leukaemia. <i>Blood</i> , 2008, 112, 4212-4212.	0.6	0
167	Dasatinib restores full donor chimerism in a patient with imatinib-resistant Ph+ ALL relapsing after unrelated cord blood transplantation. <i>Leukemia and Lymphoma</i> , 2007, 48, 2054-2057.	0.6	7
168	Report of a novel kindred with antithrombin heparin-binding site variant (47 Arg to His): Demand for an automated progressive antithrombin assay to detect molecular variants with low thrombotic risk. <i>Thrombosis and Haemostasis</i> , 2007, 98, 695-697.	1.8	27
169	Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2007, 82, 787-791.	2.0	39
170	High prevalence of the JAK2 V617F mutation in patients with extrahepatic portal vein thrombosis. <i>Hepatology</i> , 2007, 45, 831-832.	3.6	14
171	Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2007, 31, 253-256.	0.4	20
172	MTHFR polymorphisms influence on outcome and toxicity in acute lymphoblastic leukemia patients. <i>Leukemia Research</i> , 2007, 31, 1669-1674.	0.4	53
173	Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection. <i>Bone Marrow Transplantation</i> , 2007, 40, 245-249.	1.3	46
174	Kinetics of peg-filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2007, 40, 579-583.	1.3	4
175	The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. <i>Leukemia</i> , 2007, 21, 110-120.	3.3	132
176	Reply to "Absence of JAK-2 (Val617Phe) point mutations in multiple myeloma" by Dr Qin Huang et al. referred to "Screening of JAK2 V617F mutation in multiple myeloma" from Fiorini A et al. published in <i>Leukemia</i> 2006, October 20. <i>Leukemia</i> , 2007, 21, 814-815.	3.3	2
177	Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia. <i>Leukemia</i> , 2007, 21, 1819-1821.	3.3	20
178	Analysis of BCL-6, CD95, PIM1, RHO/TTF and PAX5 mutations in splenic and nodal marginal zone B-cell lymphomas suggests a particular B-cell origin. <i>Leukemia</i> , 2007, 21, 1821-1824.	3.3	24
179	Assessment of cellular origin and EBV status in a PTLD after double cord blood transplantation. <i>Leukemia</i> , 2007, 21, 2552-2554.	3.3	13
180	Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 708-714.	1.9	203

#	ARTICLE	IF	CITATIONS
181	Screening of JAK2 V617F mutation in multiple myeloma. <i>Leukemia</i> , 2006, 20, 1912-1913.	3.3	20
182	Eradication of JAK2 V617F mutation after allogeneic transplantation in a patient with myelofibrosis with myeloid metaplasia. <i>Leukemia</i> , 2006, 20, 2198-2199.	3.3	6
183	Analysis of MTHFR polymorphisms and P16 methylation and their correlation with clinical biological features of multiple myeloma. <i>Annals of Hematology</i> , 2006, 85, 474-477.	0.8	17
184	Mitoxantrone, carboplatin, cytosine arabinoside, and methylprednisolone followed by autologous peripheral blood stem cell transplantation. <i>Cancer</i> , 2006, 106, 859-866.	2.0	11
185	Imatinib for secondary Ph+ acute lymphoblastic leukemia induces response in concomitant GBM. <i>Annals of Oncology</i> , 2006, 17, 720-721.	0.6	3
186	Antituberculosis Therapy and Imatinib for Chronic Myeloid Leukemia. <i>Clinical Infectious Diseases</i> , 2006, 43, 1223-1223.	2.9	3
187	Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. <i>Blood</i> , 2005, 105, 4820-4827.	0.6	221
188	The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1985-1992.	1.9	206
189	The treatment of menorrhagia in female stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2005, 35, 827-827.	1.3	1
190	Immune recovery after low-dose Campath therapy in a group of pretreated patients affected by B-cell chronic lymphocytic leukemia. <i>Leukemia</i> , 2005, 19, 153-154.	3.3	7
191	Rituximab for pure red cell aplasia after ABO-mismatched allogeneic peripheral blood progenitor cell transplantation. <i>Transfusion</i> , 2005, 45, 643-645.	0.8	18
192	Secondary Ph+ acute lymphoblastic leukemia after temozolomide. <i>Annals of Hematology</i> , 2005, 84, 760-762.	0.8	42
193	Immune Recovery of Lymphocyte Subsets 6 Years after Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) for Lymphoproliferative Diseases. A Comparison between NHL, HD and MM in Group of 149 Patients. <i>Leukemia and Lymphoma</i> , 2004, 45, 2063-2070.	0.6	10
194	Glycoprotein Ia C807T gene polymorphism and increased risk of recurrent acute coronary syndromes: a five year follow up. <i>British Heart Journal</i> , 2004, 90, 567-569.	2.2	9
195	Glutamine parenteral supplementation in stem cell transplant. <i>Bone Marrow Transplantation</i> , 2004, 33, 455-455.	1.3	5
196	Retrospective comparison of qualitative and quantitative reverse transcriptase polymerase chain reaction in diagnosing and monitoring the ALL1-AF4 fusion transcript in patients with acute lymphoblastic leukaemia. <i>Leukemia</i> , 2004, 18, 1824-1830.	3.3	5
197	Hormonal replacement therapy after stem cell transplantation. <i>Maturitas</i> , 2004, 49, 327-333.	1.0	33
198	Sustained Signaling through the B-Cell Receptor Induces Mcl-1 and Promotes Survival of Chronic Lymphocytic Leukemia B-Cells. <i>Blood</i> , 2004, 104, 178-178.	0.6	5

#	ARTICLE	IF	CITATIONS
199	Methylenetetrahydrofolate reductase genotypes do not play a role in acute lymphoblastic leukemia pathogenesis in the Italian population. <i>Haematologica</i> , 2004, 89, 139-44.	1.7	41
200	Efficacy of granulocyte transfusions for neutropenia-related infections: retrospective analysis of predictive factors. <i>Cytotherapy</i> , 2003, 5, 19-30.	0.3	42
201	The Use of Positron Emission Tomography with [18F] 2-Fluoro-d-2-Deoxyglucose (FDG-PET) in Hodgkin and Non-Hodgkin's Lymphoma. <i>Hematology</i> , 2003, 8, 403-408.	0.7	0
202	Fine granularity clustering for large scale placement problems. , 2003, , .		33
203	Increased prevalence of the G20210A prothrombin gene variant in acute coronary syndromes without metabolic or acquired risk factors or with limited extent of disease. <i>European Heart Journal</i> , 2002, 23, 26-30.	1.0	38
204	Successful Treatment with Caspofungin of Hepatosplenic Candidiasis Resistant to Liposomal Amphotericin B. <i>Clinical Infectious Diseases</i> , 2002, 35, 1135-1136.	2.9	41
205	Negative prognostic value of glutathione S-transferase(GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. <i>Blood</i> , 2002, 100, 2703-2707.	0.6	110
206	Therapy-related MDS and AML in acute promyelocytic leukemia. <i>Blood</i> , 2002, 100, 1928-1930.	0.6	22
207	Highly active antiretroviral therapy and allogeneic CD34+ peripheral blood progenitor cells transplantation in an HIV/HCV coinfectd patient with acute myeloid leukemia. <i>Experimental Hematology</i> , 2002, 30, 279-284.	0.2	36
208	Kinetics of hemopoietic recovery after peripheral blood stem cell transplantation: Impact of stem cell purification and G-CSF. <i>American Journal of Hematology</i> , 2002, 69, 7-14.	2.0	0
209	Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. <i>Annals of Oncology</i> , 2002, 13, 1915-1918.	0.6	125
210	Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies. <i>Haematologica</i> , 2002, 87, 59-66.	1.7	8
211	Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism related enzymes in patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2001, 33, A120.	0.4	0
212	Non-Tunneled Central Venous Catheters in Adult Stem Cell Transplantation Recipients: An Effective Option. <i>Journal of Vascular Access</i> , 2001, 2, 168-174.	0.5	1
213	Molecular and clinical follow-up after stem cell transplantation for multiple myeloma. <i>Annals of Hematology</i> , 2001, 80, 90-95.	0.8	4
214	The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. <i>British Journal of Haematology</i> , 2001, 113, 630-635.	1.2	80
215	The C807T/G873A polymorphism in the platelet glycoprotein Ia gene and the risk of acute coronary syndrome in the Italian population. <i>British Journal of Haematology</i> , 2001, 114, 150-154.	1.2	24
216	The association of severe aplastic anaemia with the philadelphia chromosome and the bcr/abl transcript. <i>British Journal of Haematology</i> , 2001, 114, 954-962.	1.2	1

#	ARTICLE	IF	CITATIONS
217	Immune reconstitution after autologous selected peripheral blood progenitor cell transplantation: comparison of two CD34+ cell-selection systems. <i>Transfusion</i> , 2001, 41, 783-789.	0.8	21
218	Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells in multiple myeloma The issue of safety. <i>Experimental Hematology</i> , 2001, 29, 1-2.	0.2	1
219	Clonal hemopoiesis and risk of thrombosis in young female patients with essential thrombocythemia. <i>Experimental Hematology</i> , 2001, 29, 670-676.	0.2	51
220	Immune reconstitution after autologous peripheral blood progenitor cell transplantation. <i>Experimental Hematology</i> , 2001, 29, 1503-1516.	0.2	28
221	Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2001, 96, 2677-2682.	0.2	88
222	Prevalence of factor V Leiden and the G20210A prothrombin-gene mutation in inflammatory bowel disease. <i>Blood Coagulation and Fibrinolysis</i> , 2000, 11, 499-503.	0.5	33
223	MiCMA: An alternative treatment for refractory or recurrent Hodgkin's disease. <i>Annals of Oncology</i> , 2000, 11, 867-871.	0.6	8
224	Secondary myelodysplastic syndromes following peripheral blood stem cell transplantation: morphological, cytogenetic and clonality evaluation and the limitation of FAB criteria. <i>Bone Marrow Transplantation</i> , 2000, 26, 241-242.	1.3	7
225	Early viral complications after autologous CD34-selected peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2000, 26, 587-588.	1.3	5
226	Persistent immunological changes 55 months after PBPCT. Is the restoration of immune function possible with a longer follow-up?. <i>Bone Marrow Transplantation</i> , 2000, 26, 707-708.	1.3	2
227	Autologous Graft-Versus-Host Disease after CD34+-Purified Autologous Peripheral Blood Progenitor Cell Transplantation. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2000, 9, 375-379.	1.8	15
228	Genetic Risk Factors for Superficial Vein Thrombosis. <i>Thrombosis and Haemostasis</i> , 1999, 82, 1215-1217.	1.8	121
229	Cerebral Vein Thrombosis not Related to Use of Oral Contraceptives in a 7-year-old Child Carrier of the Prothrombin 20210A Allele. <i>Thrombosis and Haemostasis</i> , 1999, 81, 991-992.	1.8	2
230	Hormonal Therapy After Stem Cell Transplantation and the Risk of Venous Occlusive Disease. <i>Blood</i> , 1999, 93, 3154-3154.	0.6	9
231	Prevalence of mild hyperhomocysteinemia and association with thrombophilic genotypes (factor V Tj ETQq1 1 0.784314 rgBT / Over). <i>Journal of Haematology</i> , 1999, 106, 564-568.	1.2	50
232	Factor V Leiden and allogeneic bone marrow transplantation: chimerism as a confounding factor in genetic test interpretation. <i>International Journal of Laboratory Hematology</i> , 1999, 21, 401-402.	0.2	1
233	Highly fluorescent reticulocyte count predicts haemopoietic recovery after immunosuppression for severe aplastic anaemia. <i>International Journal of Laboratory Hematology</i> , 1999, 21, 387-389.	0.2	14
234	Non-invasive ventilatory support in the management of respiratory failure after autologous peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 1999, 23, 527-527.	1.3	2

#	ARTICLE	IF	CITATIONS
235	Optimal timing of G-CSF administration after CD34+immunoselected peripheral blood progenitor cell transplantation. <i>Bone Marrow Transplantation</i> , 1999, 23, 1245-1250.	1.3	28
236	Inappropriate antidiuretic hormone secretion after high-dose thiotepa. <i>Bone Marrow Transplantation</i> , 1999, 24, 571-572.	1.3	8
237	The Risk of Recurrent Deep Venous Thrombosis among Heterozygous Carriers of Both Factor V Leiden and the G20210A Prothrombin Mutation. <i>New England Journal of Medicine</i> , 1999, 341, 801-806.	13.9	467
238	Hormonal Therapy After Stem Cell Transplantation and the Risk of Venous-occlusive Disease. <i>Blood</i> , 1999, 93, 3154-3154.	0.6	0
239	Luteinizing hormone-releasing hormone analogue: leuprorelin acetate for the prevention of menstrual bleeding in premenopausal women undergoing stem cell transplantation. <i>Bone Marrow Transplantation</i> , 1998, 21, 821-823.	1.3	32
240	Long-lasting complete remission in plasma cell leukemia after aggressive chemotherapy and CD34-selected autologous peripheral blood progenitor cell transplant: molecular follow-up of minimal residual disease. <i>Bone Marrow Transplantation</i> , 1998, 22, 823-825.	1.3	11
241	Additional genetic risk factors for venous thromboembolism in carriers of the factor V Leiden mutation. <i>British Journal of Haematology</i> , 1998, 103, 871-876.	1.2	60
242	The Hohn catheter in the management of haemopoietic stem cell transplant recipients. <i>European Journal of Cancer Care</i> , 1998, 7, 201-205.	0.7	2
243	Epidemiology of Factor V Leiden: Clinical Implications. <i>Seminars in Thrombosis and Hemostasis</i> , 1998, 24, 367-379.	1.5	207
244	Prothrombin G20210A Mutant Genotype Is a Risk Factor for Cerebrovascular Ischemic Disease in Young Patients. <i>Blood</i> , 1998, 91, 3562-3565.	0.6	222
245	Incidence of Sepsis After Peripheral Blood Progenitor Cells Transplantation: Analysis of 86 Consecutive Hemato Oncological Patients. <i>Leukemia and Lymphoma</i> , 1998, 30, 193-197.	0.6	13
246	Prevalence of the 677C to T Mutation in the Methylenetetrahydrofolate Reductase Gene in Italian Patients with Venous Thrombotic Disease. <i>Thrombosis and Haemostasis</i> , 1998, 79, 686-687.	1.8	16
247	Prevalence of the Factor II G20210A Mutation in Symptomatic Patients with Inherited Thrombophilia. <i>Thrombosis and Haemostasis</i> , 1998, 80, 342-343.	1.8	14
248	Hepatic Vein Thrombosis in a Patient with Mutant Prothrombin 20210A Allele. <i>Thrombosis and Haemostasis</i> , 1998, 80, 519-519.	1.8	11
249	Prothrombin G20210A Mutant Genotype Is a Risk Factor for Cerebrovascular Ischemic Disease in Young Patients. <i>Blood</i> , 1998, 91, 3562-3565.	0.6	6
250	The Growth of Primary Low-Grade B-Cell Gastric Lymphoma Is Sustained by <i>Helicobacter pylori</i> . <i>Scandinavian Journal of Gastroenterology</i> , 1997, 32, 285-287.	0.6	27
251	Prevalence of Mutated Factor V ARG506 to GLN in Italians. <i>Thrombosis and Haemostasis</i> , 1997, 77, 216-217.	1.8	5
252	Treatment and prophylaxis of hypermenorrhea with leuprorelin in premenopausal women affected by acute leukemia at diagnosis. , 1996, 51, 248-249.		18

#	ARTICLE	IF	CITATIONS
253	Morganella morganii Pericarditis After Resolvent Splenectomy for Immune Pancytopenia Following Allogeneic Bone Marrow Transplantation for Acute Lymphoblastic Leukemia. Clinical Infectious Diseases, 1995, 21, 1052-1053.	2.9	19